Jinwon Life Sciences Confirms Autoimmune Uveitis Treatment Effect of 'Jenuzolac'

GeneOne Life Science announced on the 25th that it has confirmed the efficacy of the oral low-molecular-weight immunomodulator ‘GLS-1027’ (generic name: Genuzolac) for autoimmune uveitis.

This study is a randomized comparative study conducted in collaboration with the College of Veterinary Medicine at Cornell University in the United States, targeting dogs as experimental animals. Detailed research results are scheduled to be presented at the American College of Veterinary Ophthalmologists on the 22nd of next month.

According to the company, idiopathic and non-infectious uveitis, which are autoimmune diseases, are major causes of blindness in dogs, horses, and humans. Corticosteroids are mainly used as the primary treatment for uveitis when there are no underlying diseases, but the company explained that long-term administration can cause serious side effects.

As part of its strategy to expand the indications of GLS-1027, GeneOne Life Science plans to initiate efficacy evaluation studies for the treatment of inflammatory bowel disease (IBD) in dogs. IBD is a common disease in dogs, cats, and humans, with symptoms such as diarrhea, vomiting, weight loss, loss of appetite, and bloody stools. Although it can be partially treated with steroids, the company explained that it is a rare disease requiring alternative treatments due to severe side effects.

GeneOne Life Science previously published the mechanism of action of GLS-1027 for the treatment of autoimmune and various inflammatory diseases in an international academic journal.

A representative from GeneOne Life Science stated, “GLS-1027 has been proven to successfully treat corticosteroid-resistant uveitis in Cavalier King Charles Spaniel dogs,” and added, “This study demonstrated that GLS-1027 is as effective as the non-steroidal anti-inflammatory drug Carprofen as an adjunctive treatment for idiopathic uveitis and can be used as a steroid-sparing agent.”

Park Young-geun, CEO of GeneOne Life Science, said, “GLS-1027 is an inflammatory disease treatment with high development value and has great potential to be utilized for treating various diseases in humans and animals through indication expansion,” and added, “We expect it to be an effective treatment that can alleviate inflammation and reduce systemic steroid administration in patients with refractory uveitis.”

This content was produced with the assistance of AI translation services.